In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith statement on Related Party Transactions of the Company for the period ended 30th September, 2021, in the required format
Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2021 ,inter alia, to consider and approve 1. The unaudited Financial Results of the Company for the Quarter and half year ended 30th September 2021. 2. Limited Review Report from the Statutory Auditors of the Company.
Eiko Lifesciences Ltd - 540204 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Avi Vijaykumar MundechaDesignation :- Company Secretary and Compliance Officer
This is to inform you that pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 read with the Company''s Code of Conduct to Regulate, Monitor and Report Trading by designated persons & their immediate relatives (including all insiders), the Trading Window in respect of dealings in the Equity Shares of the Company, will remain closed, for all the designated persons of the Company & their immediate relatives (including all insiders ), with effect from 01st October, 2021 till the end of forty eight hours after the declaration of the Un-audited Financial Results of the Company for the quarter and half-year ending 30th September, 2021.